Variable | Intravesical RFS | Overall RFS | ||||||
---|---|---|---|---|---|---|---|---|
 | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
 | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value |
Age, continuous | 0.99 (0.96–1.01) | 0.359 | 0.98 (0.96–1.01) | 0.239 | 1.00 (0.99–1.01) | 0.981 | 0.99 (0.97–1.01) | 0.232 |
Gender | ||||||||
 Male | 1 | 0.181 | 1 | 0.07 | 1 | 0.94 | 1 | 0.258 |
 Female | 0.59 (0.28–1.3) |  | 0.45 (0.19–1.07) |  | 1.02 (0.69–1.50) |  | 0.77 (0.48–1.22) |  |
Smoking | ||||||||
 No | 1 | 0.273 | 1 | 0.357 | 1 | 0.021 | 1 | 0.057 |
 Yes | 1.41 (0.76–2.58) |  | 1.41 (0.68–2.89) |  | 1.54 (0.07–2.22) |  | 1.52 (0.99–2.33) |  |
Previous hydronephrosis | ||||||||
 No | 1 | 0.768 | 1 | 0.269 | 1 | 0.08 | 1 | 0.83 |
 Yes | 1.10 (0.59–2.03) |  | 0.65 (0.30–1.40) |  | 1.41 (0.96–2.08) |  | 0.94 (0.56–1.59) |  |
Previous bladder urothelial carcinoma | ||||||||
 No | 1 | 0.394 | 1 | 0.491 | 1 | 0.8 | 1 | 0.291 |
 Yes | 1.56 (0.56–4.7) |  | 0.65 (0.19–2.24) |  | 1.10 (0.52–2.37) |  | 1.60 (0.67–3.84) |  |
Concomitant bladder urothelial carcinoma | ||||||||
 No | 1 | 0.048 | 1 | 0.014 | 1 | 0.369 | 1 | 0.585 |
 Yes | 1.95 (1.01–3.76) |  | 2.71 (1.22–5.99) |  | 1.23 (1.79–1.91) |  | 1.15 (0.70–1.89) |  |
Laterality | ||||||||
 Left | 1 | 0.276 | 1 | 0.573 | 1 | 0.789 | 1 | 0.534 |
 Right | 1.38 (0.77–2.48) |  | 1.20 (0.64–2.24) |  | 0.95 (0.68–1.35) |  | 1.13 (0.78–1.64) |  |
Tumor location | ||||||||
 Renal pelvis | 1 | 0.093 | 1 | 0.129 | 1 | 0.001 | 1 | 0.003 |
 Ureter | 1.67 (0.89–3.17) |  | 1.57 (0.65–3.78) |  | 1.25 (0.86–1.80) |  | 1.60 (0.96–2.67) |  |
 Renal pelvis and ureter | 2.82 (1.02–7.78) |  | 3.72 (1.04–13.25) |  | 3.15 (1.74–5.71) |  | 3.52 (1.70–7.26) |  |
Tumor size, continuous | 0.90 (0.76–1.06) | 0.209 | 0.91 (0.74–1.11) | 0.353 | 1.07 (0.98–1.17) | 0.112 | 1.02 (0.92–1.13) | 0.682 |
Tumor focality | ||||||||
 Unifocal | 1 | 0.608 | 1 | 0.757 | 1 | 0.015 | 1 | 0.492 |
 Multifocal | 1.17 (0.65–2.09) |  | 1.12 (0.56–2.23) |  | 1.54 (1.09–2.17) |  | 1.15 (0.77–1.72) |  |
LVI | ||||||||
 No | 1 | 0.582 | 1 | 0.746 | 1 | < 0.001 | 1 | < 0.001 |
 Yes | 0.83 (0.42–1.63) |  | 0.89 (0.43–1.83) |  | 2.20 (1.54–3.13) |  | 2.03 (1.39–2.96) |  |
Tumor grade | ||||||||
 Low | 1 | 0.91 | 1 | 0.525 | 1 | < 0.001 | 1 | < 0.001 |
 High | 0.97 (0.54–1.74) |  | 0.79 (0.39–1.62) |  | 3.72 (2.41–5.73) |  | 2.47 (1.51–4.03) |  |
pT stage | ||||||||
 pT1 | 1 | 0.434 | 1 | 0.471 | 1 | < 0.001 | 1 | < 0.001 |
 pT2 | 1.48 (0.70–3.10) |  | 1.18 (0.52–2.67) |  | 1.54 (0.86–2.76) |  | 1.72 (1.06–3.03) |  |
 pT3/pT4 | 0.96 (0.48–1.93) |  | 1.67 (0.73–3.78) |  | 3.46 (2.18–5.50) |  | 2.57 (1.47–4.48) |  |
pN stage | ||||||||
 pN0 | 1 | 0.097 | 1 | 0.308 | 1 | 0.489 | 1 | 0.677 |
 pNx | 1.73 (0.91–3.28) |  | 1.45 (0.71–2.94) |  | 1.13 (0.79–1.62) |  | 1.09 (0.74–1.61) |  |
Distal ureter management | ||||||||
 Extravesical | 1 | < 0.001 | 1 | < 0.001 | 1 | 0.011 | 1 | 0.129 |
 Open intravesical | 0.32 (0.18–0.59) |  | 0.25 (0.13–0.50) |  | 0.63 (0.43–0.94) |  | 0.73 (0.47–1.12) |  |
 Endoscopic | 0.17 (0.06–0.49) |  | 0.11 (0.03–0.42) |  | 0.46 (0.27–0.79) |  | 0.52 (0.27–1.01) |  |
Adjuvant chemotherapy | ||||||||
 No | 1 | 0.043 | 1 | 0.033 | 1 | 0.035 | 1 | 0.194 |
 Yes | 0.35 (0.12–0.97) |  | 0.28 (0.09–0.90) |  | 1.52 (1.03–2.26) |  | 0.74 (0.46–1.17) |  |
Type of procedure | ||||||||
 ONU | 1 | 0.211 | 1 | 0.622 | 1 | 0.082 | 1 | 0.974 |
 LNU | 0.58 (0.25–1.34) |  | 1.23 (0.46–3.65) |  | 0.66 (0.41–1.06) |  | 0.99 (0.54–1.83) |  |